# A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

> **NCT07215390** · PHASE2 · RECRUITING · sponsor: **Apellis Pharmaceuticals, Inc.** · enrollment: 240 (estimated)

## Conditions studied

- Geographic Atrophy Secondary to Age-related Macular Degeneration

## Interventions

- **DRUG:** APL-3007, pegcetacoplan (APL-2)
- **DRUG:** APL-3007, pegcetacoplan (APL-2)
- **OTHER:** Placebo, Syfovre

## Key facts

- **NCT ID:** NCT07215390
- **Lead sponsor:** Apellis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-23
- **Primary completion:** 2027-06
- **Final completion:** 2027-11
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07215390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07215390, "A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07215390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*